SAN DIEGO—(BUSINESS WIRE)—April 30, 2008—ACADIA PharmaceuticalsInc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced thatit will present at the following investor conferences:
- Deutsche Bank's 33rd Annual Health Care Conference onWednesday, May 7, 2008, at 9:30 a.m. Eastern Time at theInterContinental Boston Hotel in Boston.
- The Bank of America 2008 Health Care Conference on Wednesday,May 14, 2008, at 10:00 a.m. Pacific Time at the Four SeasonsHotel in Las Vegas.
- The JMP Seventh Annual Securities Research Conference onMonday, May 19, 2008, at 11:00 a.m. Pacific Time at TheRitz-Carlton Hotel in San Francisco.
Live webcasts of these presentations will be accessible on thecompany's website, www.acadia-pharm.com, under the investors sectionand an archived recording will be available on the website for twoweeks following the presentation.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA currently hasfive mid-to-late stage clinical programs as well as a portfolio ofpreclinical and discovery assets directed at diseases with large unmetmedical needs, including schizophrenia, Parkinson's disease psychosis,sleep maintenance insomnia, and neuropathic pain. All of the drugcandidates in ACADIA's product pipeline emanate from discoveries madeusing its proprietary drug discovery platform. ACADIA's corporateheadquarters is located in San Diego, California and it maintainsresearch and development operations in both San Diego and Malmo,Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President andChief Financial Officer
858-558-2871
SOURCE: ACADIA Pharmaceuticals Inc.